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Abstract The e¡ect of cannabinoid on the tyrosine phosphor-
ylation of focal adhesion kinase (FAK) and focal adhesion ki-
nase-related non-kinase (FRNK) was investigated in di¡erenti-
ated mouse neuroblastoma N1E-115 cells. HU-210, a potent
cannabinoid agonist, elicited a time-dependent enhancement of
tyrosine phosphorylation of FRNK, but not FAK. Pretreatment
of cells with antisense oligodeoxynucleotide targeting CB1 can-
nabinoid receptor abolished HU-210-induced FRNK tyrosine
phosphorylation. In addition, pretreatment of cells with 8-Br-
cAMP also blocked HU-210-induced FRNK tyrosine phos-
phorylation. These data demonstrated that HU-210 induces
FRNK tyrosine phosphorylation by activating Gi-coupled CB1
cannabinoid receptor in N1E-115 cells. This newly discovered,
cannabinoid-induced FRNK tyrosine phosphorylation might
be a novel mechanism for cannabinoid-induced functional
changes. 2 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
The cannabinoid system, both the cannabinoid receptors
and the endogenous cannabinoid ligands, has drawn much
attention to cannabinoid research during the past 15 years
[1^3]. So far, two cannabinoid receptors, CB1 and CB2,
have been cloned and characterized [4,5]. Both of them belong
to the superfamily of seven transmembrane domain G pro-
tein-coupled receptors, and couple to multiple signal trans-
duction pathways, which include adenylyl cyclase, mitogen-
activated protein kinase and ion channels [1^3]. The CB1
cannabinoid receptor is found in the central nervous and pe-
ripheral systems, whereas the CB2 cannabinoid receptor is
expressed predominantly in the peripheral tissues such as the
cells of the immune system [4^6]. In the brain, CB1 cannabi-
noid receptor is distributed predominantly in cortex, basal
ganglia, cerebellum and hippocampus [6^9]. Based upon the
anatomical distribution of CB1 cannabinoid receptors and the
pharmacological e¡ects of cannabinoid compounds, the en-
dogenous cannabinoid system has been proposed to be in-
volved in the control of movement, cognition, learning, mem-
ory and brain developments.
Focal adhesion kinase (FAK), one of the non-receptor pro-
tein tyrosine kinases, is a key tyrosine kinase that is involved
in transmembrane transmission of signals from the extracellu-
lar milieu to the cell cytoskeleton and nucleus [10^13]. It has
been demonstrated that FAK plays an important role in reg-
ulating cell morphology, migration, growth, and survival.
FAK has been shown to associate with multiple signaling
proteins such as Src family protein tyrosine kinases, p130Cas,
Shc, Grb2, and phosphatidylinositol 3-kinase. These associa-
tions enable FAK to function within a signaling network that
stimulates a diversity of target pathways. Numerous studies
have demonstrated that tyrosine phosphorylation of FAK
plays an important role in regulating the functions of this
enzyme. Focal adhesion kinase-related non-kinase (FRNK),
the C-terminal non-catalytic domain of FAK, is expressed
selectively in certain tissues. It has been suggested to be an
endogenous regulatory mechanism that negatively regulates
the tyrosine phosphorylation and the activity of FAK [14^16].
A number of cell surface receptors have been found to
mediate tyrosine phosphorylation of FAK. These include in-
tegrins, receptor tyrosine kinases, receptors for neuropeptide,
neurotransmitters, chemokines and bioactive lipids [17]. Pre-
viously, it has been shown that activation of CB1 cannabinoid
receptors in rat hippocampal slices leads to enhanced tyrosine
phosphorylation of FAK+, a FAK subtype [18]. Recently, we
reported that activation of transfected CB1 cannabinoid re-
ceptors in HEK293 cells results in cell migration [19], and
activation of endogenously expressed CB1 cannabinoid recep-
tors in mouse neuroblastoma N1E-115 cells leads to neurite
remodeling [20]. Taken together, these previous studies sug-
gest that CB1 cannabinoid receptors may mediate cell cyto-
skeletal, morphological, and functional changes by coupling
to FAK-related signaling pathways.
In the present study, using morphologically di¡erentiated
mouse neuroblastoma N1E-115 cells, experiments were ¢rst
performed to determine the e¡ect of HU-210, a cannabinoid
agonist, on tyrosine phosphorylation of FAK and FRNK.
Furthermore, experiments were conducted to test the hypoth-
esis that HU-210-induced tyrosine phosphorylation of FRNK
is mediated by activation-speci¢c CB1 cannabinoid receptors
and a decrease of intracellular cAMP levels.
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2. Materials and methods
2.1. Materials
Mouse neuroblastoma N1E-115 cells were obtained from the Amer-
ican Type Culture Collection (Rockville, MD, USA). Cell culture
medium and supplements were purchased from Biowhittaker (Wal-
kersville, MD, USA). HU-210 was purchased from Tocris (Balwin,
MO, USA). Goat and rabbit polyclonal anti-FAK antibodies (clone
C-20) and mouse monoclonal anti-phosphotyrosine antibody (PY-20)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Protein A-conjugated Sepharose CL-4B beads were purchased
from Amersham Pharmacia Biotech AB (Piscataway, NJ, USA).
Phosphorothioate oligodeoxynucleotides (ODN) were purchased
from Integrated DNA Technologies (Coralville, IA, USA).
2.2. Cell culture and treatments
Mouse neuroblastoma N1E-115 cells were maintained in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM)^10% fetal calf serum supple-
mented with penicillin and streptomycin at 37‡C in an atmosphere of
humidi¢ed air and 5% CO2. Cells were cultured in serum-free DMEM
for 48 h before receiving cannabinoid treatment. More than 85% of
the cells became £attened and about 40% extended neurite under these
conditions.
Antisense pretreatment was performed according to a procedure
published by Hunter and Burstein [21] using phosphorothioate
ODN. The antisense probe is an 18-mer (5P-GTACTGAATGT-
CATTTGA-3P), complementary to positions 73^90 of the mouse
CB1 cannabinoid receptor mRNA codon. The corresponding 18-
mer sense fragment, 5P-TCAAATGACATTCAGTAC-3P, was synthe-
sized and used as a control. The antisense sequence was compared
with sequences deposited in the GenBank/EMBL data banks and
revealed no identity with other rodent sequences. N1E-115 cells
were pretreated with 3 WM antisense or sense control ODN for 48 h
in serum-free DMEM at 37‡C in an atmosphere of humidi¢ed air and
5% CO2. Following antisense ODN pretreatment, the cells were used
in cAMP accumulation and FAK immunoprecipitation experiments.
2.3. cAMP accumulation assay
cAMP accumulation assays were performed as described previously
with slight modi¢cations [22,23]. Brie£y, HU-210 was diluted with
DMEM medium containing 50 mg/ml fatty acid-free bovine serum
albumin in silanized test tubes, and 25 Wl solutions with di¡erent
drug concentrations were added to individual tubes. Forskolin was
also added to the test tubes in a volume of 25 Wl to reach a ¢nal
concentration of 1.0 WM. Con£uent cells were lifted from culture
plates with phosphate-bu¡ered saline containing 0.5 mM EDTA.
After washing with medium, the cells were incubated with phospho-
diesterase inhibitor RO20-1724 for 10 min. The stimulation of cAMP
synthesis was initiated by adding cells to test tubes that contain for-
skolin and HU-210. The ¢nal reaction volume was 250 Wl with 1U106
cells per tube and the reaction mixture was incubated at 37‡C for
5 min. The reaction was stopped with the addition of an equal volume
of 0.1 N HCl. An aliquot of 50 Wl reaction supernatant was removed
for cAMP radioimmunoassay, using a kit from DuPont-NEN (Du-
Pont-NEN, Wilmington, DE, USA).
2.4. Cell lysis, immunoprecipitation and Western blot
Cells were treated with 10 nM HU-210 for di¡erent time periods.
The cells were then lysed on ice in cell lysis bu¡er containing 20 mM
Tris^HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM EDTA, 1 mM glycerophosphate, 1 mM
EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl £uoride,
2 Wg/ml aprotinin, 1 WM leupeptin and 1 mM Na3VO4. After centri-
fugation at 10 000Ug for 20 min, the supernatants were collected. The
anti-FAK immunocomplex was prepared by incubating the superna-
tants with a goat polyclonal anti-FAK antibody at 4‡C overnight. The
protein A-conjugated Sepharose beads (protein A Sepharose CL-4B)
were added, and the mixture was incubated at 4‡C for 2 h. Subse-
quently, the protein A beads containing the immunocomplex were
washed twice with cell lysis bu¡er, and boiled with 2ULaemmli sam-
ple bu¡er for 5 min. After 10 min centrifugation at 5000Ug, the
supernatants were loaded to a SDS^polyacrylamide gel, electropho-
resed, and transferred onto a nitrocellulose membrane. The tyrosine
phosphorylation of FAK was detected with a mouse monoclonal anti-
phosphotyrosine antibody (PY-20) as the ¢rst antibody and visualized
using an ECL kit from Amersham. The loading of FAK protein was
checked with a rabbit polyclonal anti-FAK antibody.
2.5. Data analysis
Results from cAMP accumulation assays represent the meanT
S.E.M. values obtained from three independent experiments. Statisti-
cal di¡erences between di¡erent treatment groups were determined by
one-way ANOVA. A P value of 6 0.05 was considered statistically
signi¢cant.
3. Results
3.1. E¡ect of HU-210 on tyrosine phosphorylation of FAK and
FRNK
Using the approaches of immunoprecipitation and Western
blot, we determined the e¡ect of HU-210 treatment on tyro-
sine phosphorylation of FAK and FRNK in di¡erentiated
mouse neuroblastoma N1E-115 cells. The anti-FAK antibody
(C-20) recognizes both FAK and FRNK in the immunopre-
cipitation experiments. As shown in Fig. 1, no signi¢cant
changes of tyrosine phosphorylation of FAK were found after
HU-210 treatment. However, in a time-dependent manner,
HU-210 induced an increase in tyrosine phosphorylation of
FRNK.
Fig. 1. Time course of the e¡ect of HU-210 on tyrosine phosphory-
lation of FAK and FRNK in di¡erentiated N1E-115 cells. Di¡eren-
tiated N1E-115 cells were incubated with 10 nM HU-210 for the
time period indicated, and the tyrosine phosphorylation levels of
FAK and FRNK were examined by immunoprecipitation combined
with Western blot. The immunocomplexes of FAK/FRNK mixture
were obtained using an antibody against the C-terminal end of
FAK (C-20) that hence recognizes both FAK and FRNK in the
cell lysate. The tyrosine phosphorylation levels of FAK and FRNK
were detected with Western blot using an anti-phosphotyrosine anti-
body (PY-20). Molecular masses are indicated on the left. The
Western blot shown in A is representative of three independent ex-
periments. The results from densitometric scanning of the Western
blot are shown in B.
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3.2. Lack of e¡ect of HU-210 on FAK and FRNK protein
expression levels
The possible e¡ects of HU-210 on FAK and FRNK protein
expression levels in di¡erentiated mouse neuroblastoma N1E-
115 cells were evaluated with cell lysate by Western blot. As
shown in Fig. 2, the expression level of neither FAK nor
FRNK was changed by HU-210 treatment.
3.3. E¡ect of CB1 antisense ODN treatment on HU-210-
induced cAMP accumulation and HU-210-induced tyrosine
phosphorylation of FRNK
An antisense ‘knock-down’ strategy was used to examine
the involvement of CB1 cannabinoid receptors in mediating
the HU-210-induced tyrosine phosphorylation of FRNK. As
shown in Table 1, HU-210 inhibited forskolin-stimulated
cAMP accumulation in di¡erentiated mouse neuroblastoma
N1E-115 cells. In sense control ODN-pretreated cells, HU-
210 retained its e¡ect in inhibiting forskolin-stimulated
cAMP accumulation. In contrast, in CB1 antisense ODN-pre-
treated cells, HU-210 failed to inhibit forskolin-stimulated
cAMP accumulation.
In the series of experiments using antisense strategy to
study HU-210-induced tyrosine phosphorylation of FRNK,
the cells that were pretreated with CB1 antisense ODN dem-
onstrated no tyrosine phosphorylation in response to HU-210
treatment (Fig. 3). In contrast, no signi¢cant suppression of
HU-201-induced tyrosine phosphorylation of FRNK was
found in the sense ODN pretreatment group.
Fig. 2. HU-210 induces neither FAK nor FRNK expression in dif-
ferentiated N1E-115 cells. Di¡erentiated N1E-115 cells were incuba-
ted with 10 nM HU-210 for the time period indicated, and the ex-
pression levels of FAK and FRNK were examined by Western blot.
The cell lysate was separated by SDS^PAGE and FAK and FRNK
protein levels were detected with Western blot using an antibody
against the C-terminal end of FAK (C-20) that hence recognizes
both FAK and FRNK. Molecular masses are indicated on the left.
The Western blot shown in A is representative of three independent
experiments. The results from densitometric scanning of the Western
blot are shown in B.
Table 1
E¡ect of antisense ODN pretreatment on HU-210-induced inhibition
of forskolin-stimulated cAMP accumulation
Treatment cAMP accumulation (%)
Control 100
HU-210 52.80T 19.53
Sense plus HU-210 60.50T 17.32
Antisense plus HU-210 90.20T 12.34*
Adenylate cyclase activity was determined in the presence of 10 WM
forskolin or in the presence of 10 WM forskolin plus 10 nM HU-
210. The level of forskolin-stimulated cAMP accumulation was as-
signed a value of 100%. In some experiments, N1E-115 cells were
pretreated for 48 h with 3.0 WM antisense ODN targeting CB1 can-
nabinoid receptor or corresponding sense control ODN before the
cAMP accumulation assay.
*Signi¢cantly di¡erent from the HU-210 group by one-way AN-
OVA at P6 0.05.
Fig. 3. Antisense ODN pretreatment blocks HU-210-induced tyro-
sine phosphorylation of FRNK in di¡erentiated N1E-115 cells.
N1E-115 cells were pretreated for 48 h with either 3 WM antisense
ODN targeting CB1 cannabinoid receptor, or sense control ODN,
and followed by 10 nM HU-210 treatment for 10 min. The immu-
nocomplex of FRNK was obtained using a goat antibody against
the C-terminal end of FAK (C-20) that hence recognizes both FAK
and FRNK in the cell lysate. The tyrosine phosphorylation levels of
FRNK were detected with Western blot using an anti-phosphotyro-
sine antibody (PY-20). The upper panel represents the anti-phospho-
tyrosine antibody (PY-20) Western blot, and the lower panel shows
rabbit anti-FAK antibody Western blot after stripping the same
membrane. The Western blot shown in A is representative of two
independent experiments. The results from densitometric scanning of
the Western blot are shown in B.
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3.4. E¡ect of 8-Br-cAMP pretreatment on HU-210-induced
tyrosine phosphorylation of FRNK
CB1 cannabinoid receptors are negatively coupled to ade-
nylyl cyclase via a Gi protein. To investigate whether the HU-
210-induced tyrosine phosphorylation of FRNK involves a
reduction of intracellular cAMP levels, we used 8-Br-cAMP,
a cell membrane-permeable analogue of cAMP. Pretreatment
of di¡erentiated N1E-115 cells with 8-Br-cAMP for 30 min
inhibited HU-210-induced tyrosine phosphorylation of
FRNK in a concentration-dependent manner (Fig. 4).
4. Discussion
FAK is enriched in brain, especially in hippocampal forma-
tion and young neurons, where it is located in the growth
cones [24^27]. The activity of FAK is regulated by integrin
engagement and stimulation of various membrane receptors
via the phosphorylation of its tyrosine residues [10^13].
Although it has been shown that many factors induce tyrosine
phosphorylation of FAK or its subtype FAK+ in the central
nervous system, the function and regulation of FAK in neu-
rons are still poorly understood.
Many studies have demonstrated that transfected FRNK
was able to regulate the activity and tyrosine phosphorylation
of FAK [14^16]. FRNK has been found to act as an inhibitor
of FAK by blocking the formation of focal adhesions and
constitutively reducing tyrosine phosphorylation of FAK.
These inhibitory e¡ects of FRNK were reversed by co-expres-
sion of FAK, or a point mutation of FRNK that prevents its
localization to the focal contact sites. This suggests that FAK
and FRNK compete for common binding proteins whose as-
sociation with FAK is necessary for signaling by FAK. Fur-
thermore, activated caspases have been shown to cleave FAK
to generate FRNK during apoptotic processes. Thus, FRNK
is believed to function as an endogenous regulator of FAK
that regulates both tyrosine kinase activity and cellular func-
tions [14^16].
In the current study, HU-210 was found to induce tyrosine
phosphorylation of FRNK, but not FAK in di¡erentiated
mouse neuroblastoma N1E-115 cells. To study the possible
involvement of CB1 cannabinoid receptors in the HU-210-
induced tyrosine phosphorylation of FRNK, a speci¢c CB1
antisense ODN was employed. Functional knocking down of
CB1 cannabinoid receptors was achieved by the antisense pre-
treatment, since the inhibition of forskolin-stimulated cAMP
accumulation by HU-210 was blocked by antisense but not
sense control ODN pretreatment. Pretreatment with antisense,
but not sense, control ODN also blocked HU-210-induced
tyrosine phosphorylation of FRNK in these cells. These
data indicate that HU-210-induced tyrosine phosphorylation
of FRNK was mediated by CB1 cannabinoid receptors endo-
genously expressed in the di¡erentiated N1E-115 cells. One of
the major signaling pathways of cannabinoid receptors is the
inhibition of adenylate cyclase. It has been reported previ-
ously that intracellular cAMP is an important factor in regu-
lating neurite formation and stability [28,29]. In the current
study, 8-Br-cAMP pretreatment was found to inhibit HU-210-
induced tyrosine phosphorylation of FRNK. These data sug-
gest that the induction of tyrosine phosphorylation of FRNK
is mediated by HU-210-induced reduction of intracellular
cAMP levels.
To our knowledge, this study is the ¢rst to report that
endogenous FRNK can be tyrosine-phosphorylated, and the
tyrosine phosphorylation of FRNK can be regulated by a
membrane receptor-mediated mechanism. At present, the
functional signi¢cance of HU-210-induced tyrosine phosphor-
ylation of FRNK is not clear. In previous studies, it has been
demonstrated that FAK is crucial for neurite outgrowth and
the FAK activation-induced neurite outgrow can be blocked
by overexpression of FRNK [30,31]. In a recent study, we
discovered that HU-210 induces neurite retraction in di¡er-
entiated N1E-115 cells [20]. Based on these previous ¢ndings,
one could propose that by inducing the tyrosine phosphory-
lation of FRNK, HU-210 might regulate the activity of FAK,
thereby cause neurite remodeling in di¡erentiated NIE-115
cells. Obviously, this hypothesis needs to be tested in future
studies.
In summary, in the present study we have found HU-210
treatment of di¡erentiated N1E-115 cells induces the tyrosine
phosphorylation of FRNK. Using an antisense strategy and
8-Br-cAMP, we have demonstrated that CB1 cannabinoid re-
ceptors and decreases of intracellular cAMP levels are in-
volved in HU-210-induced tyrosine phosphorylation of
FRNK. The functional signi¢cance of this newly discovered
CB1 cannabinoid receptor-mediated tyrosine phosphorylation
of FRNK remains to be elucidated.
Fig. 4. 8-Br-cAMP pretreatment blocks HU-210-induced tyrosine
phosphorylation of FRNK in di¡erentiated N1E-115 cells. N1E-115
cells were pretreated with 8-Br-cAMP for 30 min, followed by 10
nM HU-210 treatment for 10 min. The immunocomplexes of FAK/
FRNK mixture were obtained using an antibody against the C-ter-
minal end of FAK (C-20) that hence recognizes both FAK and
FRNK in the cell lysate. The tyrosine phosphorylation levels of
FAK and FRNK were detected with Western blot using an anti-
phosphotyrosine antibody (PY-20). Molecular masses are indicated
on the left. The Western blot shown in A is representative of three
independent experiments. The results from densitometric scanning of
the Western blot are shown in B.
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